Vincent Ossipow
Chief Scientific Officer (CSO) at Omega Alpha SPAC (Nasdaq OMEG)
Geneva, Geneva
Overview
Work Experience
Partner
2014 - Current
Partner at Omega Funds
2014
Partner
2014 - 2017
Omega Funds global life sciences-based investment firm that specializes in direct secondary transactions.
Chief Scientific Officer (CSO)
2021
Member of the Board of Directors
2007
Current Board Seats: -Aerium Therapeutics (USA-Switzerland, private), Board Director -Immunic (USA, NASDAQ listed), Board Director, Chairman of the Nomination Committee, prior member of the Audit Committee, prior member of the Remuneration Committee -Bioinvent (Sweden, publicly listed), Board Director, member of the Nomination Committee, prior member of the Audit Committee -Sophia Genetics (Switzerland, NASDAQ listed), Independent Board Director, member of the Remuneration Committee -Etherna Immuno-Oncology (Belgium, private), Chairman of the Audit Committee, Board Director -FoRx (Switzerland, private), Board Director, member of the Nomination Committee -Anaconda Brain (Spain, private), Board observer Prior Board of Director experience: -Andrew Alliance (Switzerland, private), Board Director, member of the Remuneration Committee. Acquired -LifeSpan (USA, private), Board Director. Acquired -Raindance Technologies (USA, private), Board Director. Acquired -Kuros Biosciences (Switzerland, publicly traded), Board Director, Chairman of the Audit Committee -Endosense (Switzerland, private), Board observer. Acquired
Partner Private Equity
2012 - 2013
Investment Manager
2007 - 2012
Faculty Member
2000 - 2007
Financial Analyst
1998 - 2000
Postdoctoral Fellow
1997 - 1998
Technology Transfer Center (TTC) facilitates partnerships between the NIH research laboratories and external partners.